"CASE COMMENTARY ON NOVARTIS AG V. UNION OF INDIA & OTHERS"
This case commentary examines Novartis AG v. Union of India, (2013) 6 SCC 1, a landmark decision on pharmaceutical patentability under Section 3(d) of the Patents Act, 1970. Novartis sought a patent for the beta crystalline form of Imatinib Mesylate, used to treat chronic myeloid leukaemia, claiming enhanced bioavailability. The Supreme Court rejected the claim, holding that "efficacy" for medicines means therapeutic efficacy, not merely improved physical properties or bioavailability. The judgment establishes a strict standard against evergreening, requiring demonstrable enhancement of curative effect for new forms of known substances. It balances intellectual-property protection with public health and access to affordable generic medicines.
Authors
- Chandan Sha
Institutions
- North Bengal University (IN)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-14
- DOI
- https://doi.org/10.5281/zenodo.24219997
- Primary Topic
- Intellectual Property Law
- Type
- article
- Field-Weighted Citation Impact
- 0.00